![conference banner](/images/conference-banner.jpeg)
Abstract
Found at the outer mitochondrial membrane, the voltage-dependent anion channel, VDAC, assumes a crucial position in the cell, serving as the main interface between mitochondrial and cellular metabolisms by mediating transport of ions and metabolites. VDAC thus functions as a gatekeeper, controlling cross-talk between mitochondria and the rest of the cell. Moreover, its location at the boundary between the mitochondria and the cytosol enables VDAC to interact with proteins that mediate and regulate the integration of mitochondrial functions with other cellular activities. Here, we review current knowledge related to the roles played by VDAC in the regulation of cell life and cell death, with relation to cancer. The current concepts of altered metabolism in cancer cells are presented with specific emphasis on mitochondrial, more specifically VDAC1-bound hexokinase (HK), facilitating and promoting the high glycolytic tumor phenotype. In this respect, the up-regulation of HK expression in tumor cells and its binding to VDAC provide both a metabolic benefit and apoptosis-suppressive capacity that offers the cell a growth advantage and increases its resistance to chemotherapy. VDAC has also been recognized as a key protein in mitochondria-mediated apoptosis since it is the proposed target for the pro- and antiapoptotic Bcl-2-family of proteins, as well as due to its function in the release of apoptotic proteins located in the inter-membranal space. These and other functions point to VDAC1 as being a rational target for the development of a new generation of therapeutics.
Keywords: Apoptosis, Bcl2 family proteins, cancer, cancer metabolism, cell death, channel, cholesterol, hexokinase, hypoxia, mitochondria, mitochondrial porin, VDAC
Current Medicinal Chemistry
Title: Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Volume: 19 Issue: 5
Author(s): V. Shoshan-Barmatz and M. Golan
Affiliation:
Keywords: Apoptosis, Bcl2 family proteins, cancer, cancer metabolism, cell death, channel, cholesterol, hexokinase, hypoxia, mitochondria, mitochondrial porin, VDAC
Abstract: Found at the outer mitochondrial membrane, the voltage-dependent anion channel, VDAC, assumes a crucial position in the cell, serving as the main interface between mitochondrial and cellular metabolisms by mediating transport of ions and metabolites. VDAC thus functions as a gatekeeper, controlling cross-talk between mitochondria and the rest of the cell. Moreover, its location at the boundary between the mitochondria and the cytosol enables VDAC to interact with proteins that mediate and regulate the integration of mitochondrial functions with other cellular activities. Here, we review current knowledge related to the roles played by VDAC in the regulation of cell life and cell death, with relation to cancer. The current concepts of altered metabolism in cancer cells are presented with specific emphasis on mitochondrial, more specifically VDAC1-bound hexokinase (HK), facilitating and promoting the high glycolytic tumor phenotype. In this respect, the up-regulation of HK expression in tumor cells and its binding to VDAC provide both a metabolic benefit and apoptosis-suppressive capacity that offers the cell a growth advantage and increases its resistance to chemotherapy. VDAC has also been recognized as a key protein in mitochondria-mediated apoptosis since it is the proposed target for the pro- and antiapoptotic Bcl-2-family of proteins, as well as due to its function in the release of apoptotic proteins located in the inter-membranal space. These and other functions point to VDAC1 as being a rational target for the development of a new generation of therapeutics.
Export Options
About this article
Cite this article as:
Shoshan-Barmatz V. and Golan M., Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy, Current Medicinal Chemistry 2012; 19 (5) . https://dx.doi.org/10.2174/092986712798992110
DOI https://dx.doi.org/10.2174/092986712798992110 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications
Mini-Reviews in Medicinal Chemistry Integrated Therapeutic Approaches in Head and Neck Cancer: The Importance of Multidisciplinary Team Management
Anti-Cancer Agents in Medicinal Chemistry Targeting Inflammatory Mediators: An Anticancer Mechanism of Thymoquinone Action
Current Medicinal Chemistry Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Molecular Docking, Antioxidant, Anticancer and Antileishmanial Effects of Newly Synthesized Quinoline Derivatives
Anti-Cancer Agents in Medicinal Chemistry β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma
Current Pharmaceutical Design Morphological Characterization of Lipid Structured Nanoparticles by Atomic Force Microscopy while Minimizing the Formation of Failed Artefacts
Current Nanomaterials Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Synthesis, In Vitro Antitumor Activity and Molecular Mechanism of Novel Furan Derivatives and their Precursors
Anti-Cancer Agents in Medicinal Chemistry Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment
Current Drug Targets Brain Tumor-Related Epilepsy
Current Neuropharmacology